| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-25 | Booth Bruce | director | Sale | 37,179 | $119.71 | $4.45M |
| 2026-06-25 | Booth Bruce | director | Sale | 112,299 | $120.66 | $13.55M |
| 2026-06-25 | Booth Bruce | director | Sale | 40,774 | $121.38 | $4.95M |
| 2026-06-25 | Booth Bruce | director | Sale | 4,977 | $122.67 | $611K |
| 2026-06-25 | Booth Bruce | director | Sale | 10,860 | $123.62 | $1.34M |
| 2026-06-25 | Booth Bruce | director | Sale | 11,711 | $124.61 | $1.46M |
| 2026-06-25 | Booth Bruce | director | Sale | 3,716 | $125.82 | $468K |
| 2026-06-25 | Booth Bruce | director | Sale | 1,609 | $126.71 | $204K |
| 2026-06-25 | Booth Bruce | director | Sale | 25,075 | $127.37 | $3.19M |
| 2026-06-25 | Booth Bruce | director | Sale | 2,197 | $128.69 | $283K |
| 2026-06-25 | Booth Bruce | director | Sale | 337 | $129.61 | $44K |
| 2026-06-25 | Booth Bruce | director | Sale | 5,144 | $119.71 | $616K |
| 2026-06-25 | Booth Bruce | director | Sale | 15,660 | $120.66 | $1.89M |
| 2026-06-25 | Booth Bruce | director | Sale | 5,689 | $121.38 | $691K |
| 2026-06-25 | Booth Bruce | director | Sale | 698 | $122.67 | $86K |
| 2026-06-25 | Booth Bruce | director | Sale | 1,517 | $123.62 | $188K |
| 2026-06-25 | Booth Bruce | director | Sale | 1,639 | $124.61 | $204K |
| 2026-06-25 | Booth Bruce | director | Sale | 522 | $125.82 | $66K |
| 2026-06-25 | Booth Bruce | director | Sale | 223 | $126.71 | $28K |
| 2026-06-25 | Booth Bruce | director | Sale | 3,507 | $127.37 | $447K |
| 2026-06-25 | Booth Bruce | director | Sale | 305 | $128.69 | $39K |
| 2026-06-25 | Booth Bruce | director | Sale | 46 | $129.61 | $6K |
| 2026-06-25 | Booth Bruce | director | Sale | 9,994 | $107.30 | $1.07M |
| 2026-06-25 | Booth Bruce | director | Sale | 159 | $108.02 | $17K |
| 2026-06-25 | Booth Bruce | director | Sale | 14,351 | $108.83 | $1.56M |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-06-26 | SCHEDULE 13D/A | BIOTECHNOLOGY VALUE FUND L P | 6.30% | 2,712,852 | view → |
| 2025-06-30 | SCHEDULE | BAKER BROS. ADVISORS LP | 9.50% | 6,666,540 | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-21 | SCHEDULE 13G | Frazier Life Sciences Acquisition Corp. II | — | — | view → |
| 2026-10-16 | SCHEDULE 13D/A | Olema Pharmaceuticals, Inc. | 9.80% | 5,946,981 | view → |
| 2026-09-21 | SCHEDULE 13G | Tyra Biosciences, Inc. | — | — | view → |
| 2026-09-18 | SCHEDULE 13G | Alector, Inc. | — | — | view → |
| 2026-08-04 | SCHEDULE 13D | Entera Bio Ltd. | 9.99% | 9,171,741 | view → |
| 2026-07-20 | SCHEDULE 13G | Research Alliance Corp IV | — | — | view → |
| 2026-07-16 | SCHEDULE 13D/A | XOMA Royalty Corp | — | 0 | view → |
| 2026-07-10 | SCHEDULE 13G | Pyxis Oncology, Inc. PYXS | — | — | view → |
| 2026-06-29 | SCHEDULE 13D/A | MoonLake Immunotherapeutics MLTX | 19.70% | 8,302,735 | view → |
| 2026-06-26 | SCHEDULE 13D/A | Kymera Therapeutics, Inc. KYMR | 6.30% | 2,712,852 | view → |
| 2026-06-04 | SCHEDULE 13G | Q32 Bio Inc. QTTB | — | — | view → |
| 2026-05-29 | SCHEDULE 13G | Research Alliance Corp III RACC | — | — | view → |
| 2026-05-27 | SCHEDULE 13G | OnKure Therapeutics, Inc. OKUR | — | — | view → |
| 2026-05-18 | SCHEDULE 13D/A | XOMA Royalty Corp XOMAP | — | 3,635,758 | view → |
| 2026-04-02 | SCHEDULE 13D/A | MoonLake Immunotherapeutics MLTX | 22.30% | 8,302,735 | view → |
| 2025-11-24 | SCHEDULE | Repare Therapeutics Inc. | 24.00% | 10,333,600 | view → |
| 2025-05-20 | SCHEDULE | XOMA Royalty Corp XOMAP | 21.60% | 2,590,303 | view → |
| 2025-01-28 | SCHEDULE | XOMA Royalty Corp XOMAP | 25.30% | 2,983,026 | view → |
| 2024-10-08 | SC | MoonLake Immunotherapeutics MLTX | — | — | view → |
| 2024-07-19 | SC | Inventiva S.A. IVEVF | — | — | view → |
Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.
See pricing →